Your email and its content will be used to provide you an answerto your message. You have the possibility to access, to modify, to rectify and to suppress any personal data concerning you.
To exercise this right, please click here.
Ipsen at a glance
The group in 2015
14 September 2016 - Paris (France)
European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in…